Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation

Blood

Volumn 112, Issue 13, 2008, Pages 5219-5227

  Kakhlon, Or ^a   Manning, Hila ^a   Breuer, William ^a   Melamed Book, Naomi ^a   Lu, Chunye ^b   Cortopassi, Gino ^b   Munnich, Arnold ^c   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Clinique de Genetique Medicale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ADENOSINE TRIPHOSPHATE; CHELATING AGENT; DEFERIPRONE; FRATAXIN; IRON; MITOCHONDRIAL DNA; SIDEROPHORE; STAUROSPORINE; IRON BINDING PROTEIN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL FUNCTION; CELL STRAIN HEK293; CYTOSOL; DNA DAMAGE; FLOW CYTOMETRY; FRIEDREICH ATAXIA; HUMAN; HUMAN CELL; IRON CHELATION; IRON OVERLOAD; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; CELL LINE; DNA DAMAGE; DNA, MITOCHONDRIAL; FRIEDREICH ATAXIA; HUMANS; IRON; IRON CHELATING AGENTS; IRON-BINDING PROTEINS; MITOCHONDRIA; OXYGEN CONSUMPTION; PYRIDONES;

EID: 58149402407     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-161919     Document Type: Article

References (52)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
2. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer. 2006;46: 554-557.
3. Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet. 2000;37:1-8.
4. Patel PI, Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency. Am J Hum Genet. 2001;69:15-24.
5. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215-217.
6. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci. 2004; 1012:179-182.
7. Youdim MBH, Stephenson G, Shachar DB. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306-325.
8. Pandolfo M. Friedreich ataxia. Semin Pediatr Neurol. 2003;10:163-172.
9. Bulteau A-L, Dancis A, Gareil M, Montagne J-J, Camadro J-M, Lesuisse E. Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med. 2007;42:1561-1570.
10. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol. 1999;46:123-125.
11. Gakh O, Park S, Liu G, et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet. 2006;15:467-479.
12. Cossee M, Puccio H, Gansmuller A, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet. 2000;9:1219-1226.
13. Puccio H, Simon D, Cossee M, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27:181-186.
14. Stehling O, Elsasser H-P, Bruckel B, Muhlenhoff U, Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet. 2004;13:3007-3015.
15. Sturm B, Bistrich U, Schranzhofer M, et al. Friedreich's ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity? J Biol Chem. 2005;280:6701-6708.
16. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57: 547-583.
17. Sohn Y-S, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. 2008;111:1690-1699.
18. Fredenburg AM, Sethi RK, Allen DD, A. Yokel R. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxy-pyridin-4-one in the rat. Toxicology. 1996;108: 191.
19. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110: 401-408.
20. Lu C, Cortopassi G. Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts. Arch Biochem Biophys. 2007;457:111-122.
21. Kingston RE, Chen CA, Rose JK. Unit 9.1: Calcium Phosphate Transfection. In: Current Protocols in Molecular Biology. Hoboken, NJ: John Wiley & Sons; 2003.
22. Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-3250.
23. Schwarzer C, Illek B, Suh JH, Remington SJ, Fischer H, Machen TE. Organelle redox of CF and CFTR-corrected airway epithelia. Free Radic Biol Med. 2007;43:300.
24. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik ZI. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem. 1997;248:31-42.
25. Drapier JC, Hibbs JB Jr. Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. Methods Enzymol. 1996;269:26-36.
26. Tong W-H, Rouault TA. Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab. 2006;3:199-210.
27. Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195-3203.
28. Li K, Besse EK, Ha D, Kovtunovych G, Rouault TA. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum Mol Genet. 2008;17:2265-2273.
29. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276: 1709-1712.
30. Kispal G, Csere P, Prohl C, Lill R. The mitochon-drial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J. 1999;18:3981-3989.
31. Foury F, Talibi D. Mitochondrial control of iron homeostasis: a genome wide analysis of gene expression in a yeast frataxin-deficient strain. J Biol Chem. 2001;276:7762-7768.
32. Hausmann A, Samans B, Lill R, Muhlenhoff U. Cellular and mitochondrial remodelling upon defects in iron-sulfur protein biogenesis. J Biol Chem. 2008;283:8318-8330.
33. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006; 13:1423-1433.
34. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol. 2007;8:870-879.
35. Napoli E, Taroni F, Cortopassi GA. Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxi-dants Redox Signal. 2006;8:506-516.
36. Wu SP, Cowan JA. Iron-sulfur cluster stability: kinetics and mechanism of ligand-promoted cluster degradation. Chem Commun (Camb). 2007;1: 82-84.
37. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 1999;456:281.
38. Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatogra-phy and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;755:203-213.
39. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatric Neurol. 2006;13:142-148.
40. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107: 4142-4148.
41. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood. 2005;105:1867-1874.
42. Zanella I, Derosas M, Corrado M, et al. The effects of frataxin silencing in He La cells are rescued by the expression of human mitochondrial ferritin. Biochim Biophys Acta. 2008;1782:90-98.
43. Vreugdenhil G, Swaak AJ, de Jeu-Jaspers C, van Eijk HG. Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxy-pyrid-4- one(L1) and transferrin and possible anti-anaemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis. 1990;49:956-957.
44. Oktay Y, Dioum E, Matsuzaki S, et al. Hypoxia-inducible factor 2α regulates expression of the mitochondrial aconitase chaperone protein frataxin. J Biol Chem. 2007;282:11750-11756.
45. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005;35:711-717.
46. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
47. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-1587.
48. Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008;23:904-907.
49. Liu G, Hider R. Iron chelator chemistry. In: Templeton D, ed. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002: 321.
50. El-Jammal A, Templeton DM. Iron-hydroxypyri-done redox chemistry: kinetic and thermodynamic limitations to Fenton activity. Inorgan Chim Acta. 1996;245:199.
51. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood. 1999;94:2128-2134.
52. Goncalves S, Paupe V, Dassa E, Rustin P. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol. 2008;8:20.